The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial
Open accessAbstract
IMPORTANCE: Hidradenitis suppurativa (HS) is a chronic inflammatory disease with a high burden for patients and limited existing therapeutic options. OBJECTIVE: To evaluate the efficacy and safety of bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin 17A and 17F in individuals with moderate to severe HS. DESIGN, SETTING, AND PARTICIPANTS: This phase 2, double-blind, placebo-controlled randomized clinical trial with an active reference arm was performed from September 22, 2017, to February 21, 2019. The study included a 2- to 4-week screening period, a 12-week treatment period, and a 20-week safety follow-up. Of 167 participants screened at multiple centers, 90 were enrolled. Eligible participants were 18 to 70 years of age with a diagnosis of moderate to severe HS 12 months or more before baseline. INTERVENTIONS: Participants with HS were randomized 2:1:1 to receive bimekizumab (640 mg at week 0, 320 mg every 2 weeks), placebo, or reference arm adalimumab (160 mg at week 0, 80 mg at week 2, and 40 mg every week for weeks 4-10). MAIN OUTCOMES AND MEASURES: The prespecified primary efficacy variable was the proportion of participants with a 50% or greater reduction from baseline in the total abscess and inflammatory nodule count with no increase in abscess or draining fistula count (Hidradenitis Suppurativa Clinical Response [HiSCR] at week 12. Exploratory variables included proportion achieving a modified HiSCR with 75% reduction of HiSCR criteria (HiSCR75) or a modified HiSCR with 90% reduction of HiSCR criteria (HiSCR90), change in Patient's Global Assessment of Pain, and Dermatology Life Quality Index total scores. RESULTS: Eighty-eight participants received at least 1 dose of study medication (61 [69%] female; median age, 36 years; range, 18-69 years). Seventy-three participants completed the study, including safety follow-up. Bimekizumab demonstrated a higher HiSCR rate vs placebo at week 12 (57.3% vs 26.1%; posterior probability of superiority equaled 0.998, calculated using bayesian analysis). Bimekizumab demonstrated greater clinical improvements compared with placebo. Improvements in the International Hidradenitis Suppurativa Severity Score (IHS4) were seen at week 12 with bimekizumab (mean [SD] IHS4, 16.0 [18.0]) compared with placebo (mean [SD] IHS4, 40.2 [32.6]). More bimekizumab-treated participants achieved positive results on stringent outcome measures compared with placebo. At week 12, 46% of bimekizumab-treated participants achieved HiSCR75 and 32% achieved HiSCR90, whereas 10% of placebo-treated participants achieved HiSCR75 and none achieved HiSCR90; in adalimumab-treated participants, 35% achieved HiSCR75 and 15% achieved HiSCR90. One participant withdrew because of adverse events. Serious adverse events occurred in 2 of 46 bimekizumab-treated participants (4%), 2 of 21 placebo-treated participants (10%), and 1 of 21 adalimumab-treated participants (5%). CONCLUSIONS AND RELEVANCE: In this phase 2 randomized clinical trial, bimekizumab demonstrated clinically meaningful improvements across all outcome measures, including stringent outcomes. Bimekizumab's safety profile was consistent with studies of other indications, supporting further evaluation in participants with HS. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03248531.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of inflammatory responses by IL-17F
Yang, X. O., Chang, S. H., Park, H., Nurieva, R., Shah, B., Acero, L., Wang, Y.-H., Schluns, K. S., Broaddus, R. R., Zhu, Z., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071978 · Cited by 739
van der Ven (2019) · doi:10.12688/f1000research · Cited by 599
Hymowitz, S. G., Filvaroff, E. H., Yin, J., Lee, J., Cai, L., Risser, P., Maruoka, M., Mao, W., Foster, J., Kelley, R. F., et al. (2001) · The EMBO Journal · doi:10.1093/emboj/20.19.5332 · Cited by 548
Comorbidities of hidradenitis suppurativa (acne inversa)
Fimmel, S., & Zouboulis, C. C. (2010) · Dermato-Endocrinology · doi:10.4161/derm.2.1.12490 · Cited by 245
Matusiak, Ł., Szczęch, J., Bieniek, A., Nowicka-Suszko, D., & Szepietowski, J. C. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.10.042 · Cited by 185
Danby, F. W., & Margesson, L. J. (2010) · Dermatologic Clinics · doi:10.1016/j.det.2010.07.003 · Cited by 85
Cited by
Kimball, A. B., Jemec, G. B. E., Alavi, A., Reguiai, Z., Gottlieb, A. B., Bechara, F. G., Paul, C., Giamarellos Bourboulis, E. J., Villani, A. P., Schwinn, A., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00022-3 · Cited by 343
Self-citationSong, Y., Li, J., & Wu, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01952-8 · Cited by 259
New and Emerging Targeted Therapies for Hidradenitis Suppurativa
Markota Čagalj, A., Marinović, B., & Bukvić Mokos, Z. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073753 · Cited by 74
Vagnozzi, E., Bruni, M., Esposito, M., & Fargnoli, M. C. (2023) · Journal of Dermatological Treatment · doi:10.1080/09546634.2023.2270091 · Cited by 11
Hidradenitis Suppurativa Tunnels: Unveiling a Unique Disease Entity
Vecin, N., Balukoff, N. C., Yaghi, M., Gonzalez, T., Sawaya, A. P., Strbo, N., Tomic-Canic, M., Lev-Tov, H., & Pastar, I. (2025) · JID Innovations · doi:10.1016/j.xjidi.2025.100350 · Cited by 10
Metadata
- Authors
- Glatt, S., Jemec, G. B. E., Forman, S., Sayed, C., Schmieder, G., Weisman, J., Rolleri, R., Seegobin, S., Baeten, D., Ionescu, L., Zouboulis, C. C., & Shaw, S.
- Venue
- JAMA Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 2021-11-01
- Volume
- 157
- Issue
- 11
- Pages
- 1279
- ISSN
- 2168-6068 (ISSN-L)
- OpenAlex
- W3194448077
- Cited by
- 172
- References
- 7
- FWCI
- 22.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.